These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
29. Predictors of response to methotrexate in early DMARD naive rheumatoid arthritis: results from the initial open-label phase of the SWEFOT trial. Saevarsdottir S; Wallin H; Seddighzadeh M; Ernestam S; Geborek P; Petersson IF; Bratt J; van Vollenhoven RF; Ann Rheum Dis; 2011 Mar; 70(3):469-75. PubMed ID: 21149498 [TBL] [Abstract][Full Text] [Related]
30. Limited value of cyclosporine A for the treatment of patients with uveitis associated with juvenile idiopathic arthritis. Tappeiner C; Roesel M; Heinz C; Michels H; Ganser G; Heiligenhaus A Eye (Lond); 2009 May; 23(5):1192-8. PubMed ID: 18551142 [TBL] [Abstract][Full Text] [Related]
31. Hodgkin's disease in a patient with juvenile rheumatoid arthritis taking weekly low dose methotrexate. Londino AV; Blatt J; Knisely AS J Rheumatol; 1998 Jun; 25(6):1245-6. PubMed ID: 9632099 [No Abstract] [Full Text] [Related]
32. The magnitude of early response to methotrexate therapy predicts long-term outcome of patients with juvenile idiopathic arthritis. Bartoli M; Tarò M; Magni-Manzoni S; Pistorio A; Traverso F; Viola S; Magnani A; Gasparini C; Martini A; Ravelli A Ann Rheum Dis; 2008 Mar; 67(3):370-4. PubMed ID: 17660217 [TBL] [Abstract][Full Text] [Related]
33. Predictors of poor response to methotrexate in polyarticular-course juvenile idiopathic arthritis: analysis of the PRINTO methotrexate trial. Vilca I; Munitis PG; Pistorio A; Ravelli A; Buoncompagni A; Bica B; Campos L; Häfner R; Hofer M; Ozen S; Huemer C; Bae SC; Sztajnbok F; Arguedas O; Foeldvari I; Huppertz HI; Gamir ML; Magnusson B; Dressler F; Uziel Y; van Rossum MA; Hollingworth P; Cawkwell G; Martini A; Ruperto N; Ann Rheum Dis; 2010 Aug; 69(8):1479-83. PubMed ID: 20525842 [TBL] [Abstract][Full Text] [Related]
34. Juvenile idiopathic arthritis - an update on pharmacotherapy. Kahn P Bull NYU Hosp Jt Dis; 2011; 69(3):264-76. PubMed ID: 22035441 [TBL] [Abstract][Full Text] [Related]
35. Anti-tumour necrosis factor-alpha treatment of juvenile idiopathic arthritis in a patient with common variable immunodeficiency. Kilic SS J Trop Pediatr; 2005 Jun; 51(3):194-5. PubMed ID: 15855303 [No Abstract] [Full Text] [Related]
36. [Medical treatment of juvenile idiopathic arthritis]. Horneff G; Augustin S Med Monatsschr Pharm; 2008 Sep; 31(9):326-36; quiz 337-8. PubMed ID: 18831464 [TBL] [Abstract][Full Text] [Related]
38. The effect of genotype on methotrexate polyglutamate variability in juvenile idiopathic arthritis and association with drug response. Becker ML; Gaedigk R; van Haandel L; Thomas B; Lasky A; Hoeltzel M; Dai H; Stobaugh J; Leeder JS Arthritis Rheum; 2011 Jan; 63(1):276-85. PubMed ID: 20954192 [TBL] [Abstract][Full Text] [Related]
39. Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry. Horneff G; De Bock F; Foeldvari I; Girschick HJ; Michels H; Moebius D; Schmeling H; Ann Rheum Dis; 2009 Apr; 68(4):519-25. PubMed ID: 18413440 [TBL] [Abstract][Full Text] [Related]
40. Methotrexate improves the health-related quality of life of children with juvenile idiopathic arthritis. Céspedes-Cruz A; Gutiérrez-Suárez R; Pistorio A; Ravelli A; Loy A; Murray KJ; Gerloni V; Wulffraat N; Oliveira S; Walsh J; Penades IC; Alpigiani MG; Lahdenne P; Saad-Magalhães C; Cortis E; Lepore L; Kimura Y; Wouters C; Martini A; Ruperto N; Ann Rheum Dis; 2008 Mar; 67(3):309-14. PubMed ID: 17875547 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]